A vaccine to prevent and treat genital herpes
Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes
This study is working on a new vaccine to help prevent and treat genital herpes, which affects many people, by using a special type of mRNA to boost the immune system against the virus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10870168 on NIH RePORTER |
What this research studies
This research focuses on developing a new vaccine using nucleoside-modified mRNA to prevent and treat genital herpes, which affects millions worldwide. The vaccine is designed to express specific proteins from the herpes simplex virus type 2 (HSV-2) to stimulate an immune response. It aims to identify immune correlates of protection by analyzing blood samples from immunized animal models. The ultimate goal is to advance this vaccine into human trials and improve our understanding of how to effectively combat genital herpes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk of genital herpes infection or those currently living with the virus.
Not a fit: Patients who are not at risk for genital herpes or those who have already developed severe complications from the infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a much-needed vaccine that prevents genital herpes infections and helps those already infected manage their condition.
How similar studies have performed: Other research has shown promise in using mRNA technology for vaccines, indicating a potential for success in this novel approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Friedman, Harvey Michael — University of Pennsylvania
- Study coordinator: Friedman, Harvey Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.